
Opinion|Videos|June 27, 2024
Insights on T-DXd and Emerging Research on ADCs in HR+/HER2-Low Breast Cancer
Author(s)Aditya Bardia, MD, MPH, Laura Huppert, MD
Laura Huppert, MD, and Aditya Bardia, MD, MPH, FASCO, share advice for community oncologists on the utilization of T-DXd and discuss the future outlook for antibody-drug conjugates in HR+/HER2-low breast cancer.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- What advice can you share for community oncologists who are using T-DXd in their practice?
- What does the future look like for ADCs in HR+/HER2-low breast cancer?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
2
Managing Toxicity and Safety of Belzutifan in ccRCC
3
Spotlighting Sequencing and Biomarkers in Bladder Cancer Management
4
Dr Shubham Pant Highlights Progress and Promise in Pancreatic Cancer Treatment
5




















